Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) have earned an average recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $23.67.
A number of research analysts recently commented on ACRV shares. KeyCorp began coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock. Cantor Fitzgerald began coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating on the stock.
Read Our Latest Stock Report on Acrivon Therapeutics
Institutional Inflows and Outflows
Acrivon Therapeutics Price Performance
Shares of NASDAQ:ACRV opened at $5.50 on Tuesday. The company’s fifty day moving average price is $5.59 and its 200-day moving average price is $6.77. The firm has a market capitalization of $171.25 million, a price-to-earnings ratio of -2.04 and a beta of 0.85. Acrivon Therapeutics has a one year low of $4.69 and a one year high of $11.90.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- Can TikTok Stock Picks Really Make You Rich?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- The “Quality” Rotation: Back to Basics Investing
- Upcoming IPO Stock Lockup Period, Explained
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.